Brother for Tape Label White on Black TZe231 TZ231 20PK P-Touch 1/2" PT-E550W Label Tapes & Cartridges


  1. Home
  2. Brother for Tape Label White on Black TZe231 TZ231 20PK P-Touch 1/2" PT-E550W
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
20PK TZ231 TZe231 Black on White Label Tape for Brother P-Touch PT-E550W 1/2"
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Unbranded

Model:

Compatible TZ-231 TZe-231

MPN:

Does Not Apply

Print Technology: Thermal Type: Compaitble P-touch TZ Serial Label Tape
Country/Region of Manufacture: China Series: Compatible Brother TZE
Compatible Brand: Brother P-touch TZ Serial Label Tape Tape Width: 1/2 in
Compatible Model: TZ-231 Color:

White

Track Number: Any tape order would be offered with track number UPC:

Does not apply






published on tue nov 09 2021

Brother for Tape Label White on Black TZe231 TZ231 20PK P-Touch 1/2" PT-E550W Label Tapes & Cartridges

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Brother for Tape Label White on Black TZe231 TZ231 20PK P-Touch 1/2" PT-E550W Label Tapes & Cartridges

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS